Related Experiment Videos
Should my outpatient center have a beta-blocker protocol?
1University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. fleishel@uphs.upenn.edu
Current Opinion in Anaesthesiology
|November 9, 2007
Summary
Perioperative beta-blockade may reduce cardiac risk in ambulatory surgery for patients already on these medications. However, initiating prophylactic beta-blockers is not recommended for those not currently taking them, especially in low-risk procedures.
Area of Science:
- Cardiology
- Anesthesiology
- Pharmacology
Background:
- Perioperative beta-blockade is recommended to reduce cardiac risk in noncardiac surgery.
- Evidence regarding its use in ambulatory surgery is limited.
Purpose of the Study:
- To review the evidence and guidelines for perioperative beta-blockade in ambulatory surgery.
- To determine the efficacy and recommendations for this patient population.
Main Methods:
- Review of existing clinical trials and guidelines.
- Analysis of studies focusing on ambulatory surgery patients undergoing noncardiac procedures.
Main Results:
- Initial studies showed benefit in high-risk vascular surgery patients with positive stress tests.
- Recent studies found no efficacy in patients without coronary artery disease undergoing major noncardiac surgery.
- Guidelines recommend continuation for patients already on beta-blockers and for those with positive stress tests undergoing vascular surgery, but not for low-risk surgery.
Conclusions:
- Patients on beta-blockers undergoing ambulatory surgery should continue their medication.
- Prophylactic beta-blocker therapy is not supported for ambulatory surgery patients not currently taking these medications.
- Further research may be needed for specific low-risk ambulatory surgery populations.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...